^
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive
:
A2
Servier Press Release - 1d
dMMR/MSI-H + TMB-L
Cholangiocarcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR
Cholangiocarcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 1wk
BRCA1 S451Lfs*20
Gallbladder Cancer
olaparib
Sensitive
:
C4
Onco Targets Ther - 2wk
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
No biomarker
Gallbladder Cancer
GC
Sensitive
:
A2
No biomarker
Gallbladder Cancer
GemOx
Sensitive
:
A2
No biomarker
Gallbladder Cancer
gemcitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
CAPOX
Sensitive
:
A2
No biomarker
Gallbladder Cancer
GEM-CAP
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
FP
Sensitive
:
A2
No biomarker
Gallbladder Cancer
CAPOX
Sensitive
:
A2
No biomarker
Gallbladder Cancer
XP
Sensitive
:
A2
No biomarker
Gallbladder Cancer
FP
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
XP
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Gallbladder Cancer
capecitabine
Sensitive
:
A2
No biomarker
Gallbladder Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Gallbladder Cancer
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Gallbladder Cancer
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
gemcitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
gemcitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
capecitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
BRAF V600E
Biliary Tract Cancer
trametinib + dabrafenib
Sensitive
:
A2
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our